Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151197 · ClinicalTrials.gov registry record · Phase 3
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
A Phase 3 study of Plantar Fibromatosis and Ledderhose Disease, sponsored by Endo Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
- 20
- Study locations
NCT06151197: Active Phase 3 study of Plantar Fibromatosis and Ledderhose Disease, sponsored by Endo Pharmaceuticals.
NCT06151197 is a Phase 3 study of Plantar Fibromatosis and Ledderhose Disease that is active but no longer recruiting, run by Endo Pharmaceuticals. The registered enrollment target is 418 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06151197, a Phase 3 study of Plantar Fibromatosis and Ledderhose Disease, is active but no longer recruiting, sponsored by Endo Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL EN3835
Study Locations (20)
California
- Endo Site 49 - Castro Valley
- Endo Site 39 - Cerritos
- Endo Site 31 - Corona
- Endo Clinical Site 2 - Encinitas
- Endo Site 8 - Fresno
- Endo Site 28 - Lancaster
- Endo Site 9 - Los Angeles
- Endo Site 53 - Los Angeles
- Endo Site 50 - San Francisco
- Endo Site 29 - Sherman Oaks
- Endo Site 30 - Tarzana
- Endo Site 61 - Torrance
Arizona
- Endo Site 42 - Mesa
- Endo Site 64 - Scottsdale
- Endo Site 11 - Tucson
Colorado
- Endo Site 47 - Johnstown
- Endo Site 65 - Parker
- Endo Site 17 - Westminster
Florida
- Endo Site 22 - Hialeah
- Endo Site 59 - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
What the registry record for NCT06151197 still lists
NCT06151197 is an interventional study that assigns participants to a tested intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Plantar Fibromatosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06151197 names 20 study sites across 4 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06151197 about?
NCT06151197 is a clinical study titled "Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)". This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
What is the current status of trial NCT06151197?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2023-11-28. Estimated completion is 2026-03.
What conditions does trial NCT06151197 study?
This clinical trial studies the following conditions: Plantar Fibromatosis, Ledderhose Disease.
What interventions are being tested in trial NCT06151197?
The interventions under investigation include: Placebo (OTHER), EN3835 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06151197?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06151197 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plantar Fibromatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06151197's enrollment target sits among peer trials
418 901st of 2000 higher than 1,099 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI